An Follow-Up Study of Liver Cirrhosis

Decompensated Liver Cirrhosis Clinical Trial

Official title:
An Observational Follow-Up Study of Patients Previously Enrolled in ADR-001-01 Study Against Liver Cirrhosis

Status Completed

Clinical Trial Summary

This is a follow-up study to assess safety and preliminary clinical activity of ADR-001 in patients with liver cirrhosis (Child-Pugh score; Grade B) caused by Hepatitis C or Nonalcoholic Steatohepatitis. Patients who have already participated in the ADR-001-01 study and completed the last evaluation after 24 weeks of administration will be eligible to this study. Patients registered will continue follow-up observation and evaluate long-term safety and exploratory efficacy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03472742
Study type	Observational
Source	Rohto Pharmaceutical Co., Ltd.
Contact
Status	Completed
Phase
Start date	March 7, 2018
Completion date	October 12, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05871463` - Effect of Mesenchymal Stem Cells-derived Exosomes in Decompensated Liver Cirrhosis	Phase 2
Recruiting	`NCT03945487` - Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis	Phase 2
Not yet recruiting	`NCT03529136` - Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis	Phase 2
Not yet recruiting	`NCT05948982` - Safety of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Decompensated Hepatitis B Cirrhosis	Phase 1/Phase 2
Completed	`NCT03254758` - A Study of ADR-001 in Patients With Liver Cirrhosis	Phase 1/Phase 2
Recruiting	`NCT04801290` - TIPS in Patients With Decompensated Liver Cirrhosis